Abstract 283P
Background
Worldwide, there are approximately 560 000 new cases diagnosed with head and neck cancer and 300 000 deaths each year. In developing countries including Sub-Saharan Africa, head and neck cancer is rare compared to other cancers. The aims of this study are to estimate the incidence and determine the epidemiological characteristics of head and neck cancer in the population of Niger.
Methods
This is a descriptive retrospective study of head and neck cancer cases, reported to the Niger Cancer Registry in the period 1992-2009. Head and neck cancer includes the following: lip, tongue, mouth (floor, palate and other), salivary glands, tonsils, pharynx (oro-, naso- and hypopharynx), larynx, nose, ear, head and neck not otherwise specified.
Results
In 1992-2009, there were 344 cases diagnosed with head and neck cancer in Niger, which was 4.89% of all cases of cancer reported during this period, with a male-female ratio of 1.49. The incidence rate of head and neck cancer was 2.34 cases per 100 000 persons. Oral cancer was the most common cancer (27.6%), followed by laryngeal and salivary glands cancers (13.1%) and tonsil cancer (10.2%). The mean age at diagnosis of the patients was 42.11±18.24 years. The commonest histological type was squamous cell carcinoma in 27.1% of cases. We registered 11 deaths, with a fatality rate of 3.19%.
Conclusions
Although the incidence rates for head and neck cancers are lower, these cancers include a diverse group of uncommon tumors that frequently are aggressive. Because of the seriousness of cancer in Niger; the health authorities should pay more attention to this pathology through efficient fight strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
434P - Pan-Canadian evidence-based, consensus-driven cancer treatment protocols/information for use at the point of care by medical oncologists? Is there a need?
Presenter: Kiran Virik
Session: e-Poster Display Session
435P - Hypnotics and risk of cancer: A meta-analysis of observational studies
Presenter: Tzu Rong Peng
Session: e-Poster Display Session
436P - Clinicopathological characteristics and outcomes of adolescent and young adult (AYA) melanoma: Results from an Asian perspective
Presenter: Wei Lin Goh
Session: e-Poster Display Session
437P - Long-term efficacy and toxicity outcome of adjuvant external beam radiotherapy for medullary thyroid cancer: A single institution cohort study
Presenter: Ka Man Cheung
Session: e-Poster Display Session
438P - Real-world data of relapse after adjuvant treatment (Tx) in high-risk melanoma
Presenter: Carolina Ortiz Velez
Session: e-Poster Display Session
439P - Immunohistochemical analysis of p53 and Ki-67 in glioblastoma (GBM) and their correlations with patient survival
Presenter: Paulo Luz
Session: e-Poster Display Session
440P - Blinded independent central review of oncology trials: The monitoring of readers' performance
Presenter: Hubert Beaumont
Session: e-Poster Display Session
441P - Influence of radiation therapy of patients with somatotropic pituitary adenomas depending on the age of patients
Presenter: Saodat Issaeva
Session: e-Poster Display Session
442P - Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
Presenter: Bhumsuk Keam
Session: e-Poster Display Session